Morning Dosing of Once-daily Glaucoma Medication is More Convenient and May Lead to Greater Adherence Than Evening Dosing

Ford, Bryce; Gooi, Malcolm; Carlsson, Anthony; Crichton, Andrew

doi:10.1097/ijg.0b013e31822e622f

Cited by 10 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The timing of daily instillations may have influenced treatment adherence, which is reported to be decreased with evening vs morning dosing. 38,39 Lastly, group sizes were relatively small and patients were predominantly white and were generally younger than those in other studies, which may limit the generalizability of study results to broader patient populations.…”

Section: Discussionmentioning

confidence: 93%

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial

Barnebey¹,

Robin

2017

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial

Barnebey¹,

Robin

2017

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In a randomized crossover study in 30 patients, treatment with travoprost alone either in the morning or evening was equally effective at lowering IOP. 224 However, in a prospective randomized crossover comparison study in 32 patients…”

Section: Glaucomamentioning

confidence: 99%

Circadian Variation in Efficacy of Medications

Walton

Walker

Bumgarner

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Although much has been learned about circadian clocks and rhythms over the past few decades, translation of this foundational science underlying the temporal regulation of physiology and behavior to clinical applications has been slow. Indeed, acceptance of the modern study of circadian rhythms has been blunted because the phenomenology of cyclic changes had to counteract the 20th century dogma of homeostasis in the biological sciences and medicine. We are providing this review of clinical data to highlight the emerging awareness of circadian variation in efficacy of medications for physicians, clinicians, and pharmacists. We are suggesting that gold‐standard double‐blind clinical studies should be conducted to determine the best time of day for optimal effectiveness of medications; also, we suggest that time of day should be tracked and reported as an important biological variable in ongoing clinical studies hereafter. Furthermore, we emphasize that time of day is, and should be considered, a key biological variable in research design similar to sex. In common with biomedical research data that have been historically strongly skewed toward the male sex, most pharmaceutical data have been skewed toward morning dosing without strong evidence that this is the optimal time of efficacy.

show abstract

“…Though some early studies of prostaglandin analogs showed pupil constriction after drop usage in humans39 and glaucomatous Beagles,40 potentially prompting recommendations for evening administration, other studies have not confirmed this finding 41–43. AM dosing of eye drops has been shown to be associated with improved adherence in some patient populations,44 and all published studies of LBN to date have been done with evening dosing. It is unknown whether the same IOP-lowering effects of LBN would be seen with AM dosing and studies comparing AM vs PM administration of LBN may be warranted in the future.…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Addis¹,

Miller-Ellis²

2018

OPTH

View full text Add to dashboard Cite

Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveoscleral pathway) with nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal. Nitric oxide-induced relaxation of the trabecular meshwork and Schlemm’s canal leads to increased outflow through the trabecular meshwork and thus lowering of IOP. LBN has now been shown in multiple clinical studies to be effective and safe. In this article, we summarize the clinical trials that led to LBN’s approval as well as the comparative studies that have been done to evaluate the efficacy of this drug as compared to other US Food and Drug Administration (FDA)-approved therapies for OAG and OHT. We then review the side effects of treatment that were seen in each of these studies. Finally, we will attempt to discuss the place of this drug in therapy for patients with OAG.

show abstract

Morning Dosing of Once-daily Glaucoma Medication is More Convenient and May Lead to Greater Adherence Than Evening Dosing

Cited by 10 publications

References 17 publications

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial

Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial

Circadian Variation in Efficacy of Medications

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Contact Info

Product

Resources

About